Favre Guillaume, Guani Benedetta, Balaya Vincent, Magaud Laurent, Lecuru Fabrice, Mathevet Patrice
Department of Gynecology, University Hospital of Lausanne, Lausanne, Switzerland.
Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Front Oncol. 2021 Feb 17;10:621518. doi: 10.3389/fonc.2020.621518. eCollection 2020.
Senticol 2 is a randomized multicenter trial in the treatment of early-stage cervical cancer patients. The aim of the Senticol 2 study was to compare the effect of sentinel-lymph-node biopsy (SLNB) to that of SLNB + pelvic lymphadenectomy (PLND), and to determine the postoperative lymphatic morbidity in the two groups. Here, we report a secondary objective of this study: the follow up.
In the Senticol 2 trial, patients underwent a laparoscopy with a sentinel-node-detection procedure and were randomized into two groups, namely: Group A, in which participants received SLNB, and Group B, in which participants received SLNB + PLND. Patients with an intra-operative macroscopically suspicious lymph node, were given a frozen-section evaluation and were randomized only if the results were negative. All of the patients received follow up with a clinical examination at 1, 3, and 6 months after surgery, and then every 3-4 months after that. The median follow up was 51 months (4 years and 3 months).
Disease-free survival after 4 years for the SLNB group and the SLNB + PLND group were 89.51% and 93.1% ( = 0.53), respectively. The only statistical factor associated with recurrence in the univariate analysis was the adjuvant radiotherapy. No other factors, including the age of the patients, histological type, tumor size, lymph vascular space invasion (LVSI), and positive nodal status, were significant in the univariate or multivariate analyses. The overall survival rates after 4 years in the SLNB and SLNB + PLND groups were 95.2% and 96% ( = 0.97), with five and four deaths, respectively. The univariate and multivariate analyses did not find any prognostic factors.
This randomized study confirmed the results of the Senticol 1 study and supports the sentinel lymph node (SLN) technique as a safe technique for use in patients with early-stage cervical cancer treated with SLNB only. Disease-free survival after 4 years was similar in patients treated with SLN biopsy and patients who underwent a lymphadenectomy.
Senticol 2是一项治疗早期宫颈癌患者的随机多中心试验。Senticol 2研究的目的是比较前哨淋巴结活检(SLNB)与SLNB +盆腔淋巴结清扫术(PLND)的效果,并确定两组患者术后的淋巴系统发病率。在此,我们报告本研究的一个次要目标:随访。
在Senticol 2试验中,患者接受了带有前哨淋巴结检测程序的腹腔镜检查,并被随机分为两组,即:A组,参与者接受SLNB;B组,参与者接受SLNB + PLND。术中肉眼可疑淋巴结的患者接受了冰冻切片评估,只有结果为阴性时才进行随机分组。所有患者在术后1、3和6个月接受临床检查随访,之后每3 - 4个月随访一次。中位随访时间为51个月(4年零3个月)。
SLNB组和SLNB + PLND组4年后的无病生存率分别为89.51%和93.1%(P = 0.53)。单因素分析中与复发相关的唯一统计因素是辅助放疗。在单因素或多因素分析中,包括患者年龄、组织学类型、肿瘤大小、淋巴血管间隙浸润(LVSI)和淋巴结阳性状态在内的其他因素均无显著意义。SLNB组和SLNB + PLND组4年后的总生存率分别为95.2%和96%(P = 0.97),分别有5例和4例死亡。单因素和多因素分析均未发现任何预后因素。
这项随机研究证实了Senticol 1研究的结果,并支持前哨淋巴结(SLN)技术作为仅接受SLNB治疗的早期宫颈癌患者的一种安全技术。接受SLN活检的患者和接受淋巴结清扫术的患者4年后的无病生存率相似。